Denali Therapeutics Inc. DNLI
20.33 USD +0.26 (+1.30%)
At closeNov 10, 2026, 7:16 AM EST
20.40 +0.07 +0.34%
Pre-market · Nov 10, 7:16 AM ET
19.76 Day range 20.56
15.18 52-week range 27.30
- YTD
- +23.14%
- 1 year
- +35.35%
News
benzinga.com Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $42 Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $40 to $42.
benzinga.com Wedbush Maintains Outperform on Denali Therapeutics, Raises Price Target to $24 Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raises the price target from $23 to $24.
benzinga.com BTIG Reiterates Buy on Denali Therapeutics, Maintains $39 Price Target BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $39 price target.
seekingalpha.com Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript
marketbeat.com Denali Therapeutics Q3 Earnings Call Highlights Denali Therapeutics NASDAQ: DNLI reported third-quarter 2026 net product revenue of $17.8 million from AVLAYAH, its treatment for Hunter syndrome, as expanding payer coverage and transitions of…
zacks.com Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $0.74 per share a year ago.- benzinga.com UPDATE: Denali Therapeutics Q3 Adj. EPS $(0.64) Misses $(0.53) Estimate, Sales $17.778M Beat $10.657M Estimate Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.53) by 20.75 percent. This is a 13.51 percent increase over losses…
benzinga.com Denali Therapeutics Q3 2026 Earnings Call Transcript Denali Therapeutics (NASDAQ:DNLI) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Denali Therapeutics Sees Q4 Sales $30.000M-$32.000M vs $22.659M Est Denali Therapeutics (NASDAQ:DNLI) sees Q4 sales of $30.000 million-$32.000 million vs $22.659 million analyst estimate.
benzinga.com Denali Therapeutics Q3 EPS $0.37 Beats $(0.59) Estimate, Sales $17.778M Beat $10.657M Estimate Denali Therapeutics (NASDAQ:DNLI) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $(0.59) by 162.71 percent. This is a 150 percent increase over losses of…
globenewswire.com Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarter Continued growth expectations drive Q4 2026 net product revenue guidance of…
benzinga.com Denali Therapeutics Q2 2026 Earnings Call Transcript On Thursday, Denali Therapeutics (NASDAQ:DNLI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to…
benzinga.com B. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35 B. Riley Securities analyst Mayank Mamtani maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $30 to $35.
benzinga.com UBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34 UBS analyst Michael Yee maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $25 to $34.- benzinga.com Denali Therapeutics Q2 EPS $(0.68) Misses $(0.65) Estimate, Sales $3.604M Miss $14.613M Estimate Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.65) by 4.62 percent. This is a 5.56 percent increase over losses of…
- benzinga.com Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $36 Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $35 to $36.
- benzinga.com Deutsche Bank Maintains Buy on Denali Therapeutics, Raises Price Target to $35 Deutsche Bank analyst David Hoang maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $31 to $35.
- benzinga.com JP Morgan Reinstates Overweight on Denali Therapeutics, Announces $29 Price Target JP Morgan analyst Jessica Fye reinstates Denali Therapeutics (NASDAQ:DNLI) with a Overweight and announces $29 price target.
- benzinga.com Denali Therapeutics Signs Deal To Sell Its Rare Pediatric Disease Priority Review Voucher For $195M Denali Therapeutics Inc. (Nasdaq: DNLI) today announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195 million.…
- benzinga.com Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35 Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $40 to $35.
- benzinga.com Biogen And Denali Discontinue BIIB122 Development In Idiopathic Parkinson's Disease After Phase 2b LUMA Trial Misses Primary And Secondary Endpoints The Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue…
benzinga.com Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $40 Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $42 to $40.- benzinga.com BTIG Reiterates Buy on Denali Therapeutics, Maintains $39 Price Target BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $39 price target.
- benzinga.com Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $23 Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and lowers the price target from $25 to $23.
benzinga.com Denali Therapeutics Q1 EPS $(0.69) Beats $(0.71) Estimate Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.71) by 2.82 percent. This is a 11.54 percent increase over losses of…
benzinga.com Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This One Plays Out' Nancy Pelosi Stock Tracker highlighted Claude AI's Denali Therapeutics earnings bet, which targets upside from its rare-disease drug launch.
benzinga.com Arista Networks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.
benzinga.com Baird Maintains Outperform on Denali Therapeutics, Raises Price Target to $34 Baird analyst Joel Beatty maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raises the price target from $32 to $34.
benzinga.com Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why Denali shares fall after Takeda exits DNL593 deal; company regains full rights and targets Phase 1/2 data readout by late 2026.- benzinga.com Reported Friday, Denali Therapeutics Regains Full Rights To DNL593 After Takeda Terminates Collaboration, Phase 1/2 FTD-GRN Trial Results Expected By End Of 2026 Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle™ technologyResults from ongoing Phase 1/2 study in patients with…
- benzinga.com Denali Therapeutics Secures $200M Royalty Funding Following U.S. FDA Accelerated Approval Of Tividenofusp Alfa Item 7.01 Regulation FD Disclosure. Royalty Agreement Closing and Funding On March 27, 2026, the Company received $200.0 million in gross proceeds in connection with the closing of the
- benzinga.com Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $42 Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $40 to $42.
- benzinga.com Goldman Sachs Maintains Buy on Denali Therapeutics, Raises Price Target to $40 Goldman Sachs analyst Salveen Richter maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $35 to $40.
- benzinga.com Stifel Maintains Buy on Denali Therapeutics, Raises Price Target to $41 Stifel analyst Paul Mattels maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $34 to $41.
benzinga.com Arm Holdings To Rally Over 27%? Here Are 10 Top Analyst Forecasts For Thursday Wall Street analysts change ratings on top stocks: BNP Paribas cuts Chewy Inc, Bernstein cuts Qualcomm, Wells Fargo raises United Natural Foods.
benzinga.com FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease Denali Therapeutic snags FDA accelerated approval for Avlayah for Hunter syndrome, analyst flags strong launch potential.- benzinga.com Baird Maintains Outperform on Denali Therapeutics, Raises Price Target to $32 Baird analyst Joel Beatty maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raises the price target from $29 to $32.
- benzinga.com HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Raises Price Target to $42 HC Wainwright & Co. analyst Andrew S. Fein maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $32 to $42.
- benzinga.com FDA Approves Denali Therapeutics' Avlayah To Treat Hunter Syndrome https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-neurologic-manifestations-hunter-syndrome
benzinga.com Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer treatment data. Hims & Hers and Xenon Pharma jump over 40%.- benzinga.com BTIG Maintains Buy on Denali Therapeutics, Raises Price Target to $36 BTIG analyst Thomas Shrader maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $32 to $36.
- benzinga.com Denali Therapeutics Q4 EPS $(0.73) Beats $(0.76) Estimate Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.76) by 4.45 percent. This is a 8.96 percent decrease over losses of…
- benzinga.com Wolfe Research Initiates Coverage On Denali Therapeutics with Peer Perform Rating Wolfe Research analyst Rudy Li initiates coverage on Denali Therapeutics (NASDAQ:DNLI) with a Peer Perform rating.
benzinga.com FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment REGENXBIO shares fall after the FDA issues a response letter on its Hunter syndrome gene therapy, raising trial design concerns and pushing the approval timeline.- benzinga.com BTIG Reiterates Buy on Denali Therapeutics, Maintains $32 Price Target BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $32 price target.
- benzinga.com Denali Therapeutics Reveals Enzyme TransportVehicle Progress Across Three Clinical Programs For Treatment of Lysosomal Storage Disorders; Analysis From Continued Follow-Up Of Phase 1/2 Clinical Trial Data In Hunter Syndrome Reinforces Potential For Tividenofusp Alfa To Address Full Disease Spectrum; Preliminary Phase 1/2 Study Data Show Treatment With DNL126 Reduced Disease Biomarkers In Cerebrospinal Fluid And Peripheral Tissue Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrumLaunch readiness…
- benzinga.com Denali Therapeutics Presents Data On Enzyme TransportVehicle Programs At 2026 WORLDSymposium Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority ReviewPreliminary data from Phase…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com Denali Therapeutics' Tividenofusp Alfa Demonstrates Biomarker And Clinical Improvements In Hunter Syndrome, Published In NEJM As FDA Review Nears April 2026 Decision Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints including adaptive behavior, cognition and hearing, and…
- benzinga.com Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $30 Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and lowers the price target from $31 to $30.